Because of the reported interactions between these two overlapping pathways by our group and others [12], we looked for evidence of pathway activation for both c-Met and EGFR in NSCLC patients, and for an increased anti-tumor effect in the HGF TG murine model from dual targeting of both HGF/c-Met and EGFR pathways. The gene discussed is HGF; the disease is neoplasm.